News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
482,531 Results
Type
Article (38415)
Company Profile (456)
Press Release (443644)
Multimedia
Podcasts (151)
Webinars (32)
Section
Business (140808)
Career Advice (1978)
Deals (24090)
Drug Delivery (155)
Drug Development (70637)
Employer Resources (202)
FDA (12039)
Job Trends (10865)
News (228006)
Policy (21801)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (4)
2027 Genetown Standard (6)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (7)
Academia (2290)
Academic (1)
Accelerated approval (53)
ADA (43)
Adcomms (28)
Allergies (183)
Alliances (26273)
ALS (206)
Alzheimer's disease (1699)
Antibody-drug conjugate (ADC) (512)
Approvals (12586)
Artificial intelligence (616)
ASCO (334)
Autoimmune disease (323)
Automation (42)
Bankruptcy (211)
Best Places to Work (8385)
BIO (56)
Biologics (1)
BIOSECURE Act (18)
Biosimilars (235)
BioSpace Insights (146)
Biotechnology (320)
Bladder cancer (202)
Brain cancer (74)
Breast cancer (790)
Cancer (5995)
Cardiovascular disease (498)
Career advice (1649)
Career pathing (43)
CAR-T (331)
CDC (42)
Celiac Disease (2)
Cell therapy (868)
Cervical cancer (51)
Clinical research (63335)
Collaboration (1731)
Commercialization (5)
Company closure (3)
Compensation (1058)
Complete response letters (92)
COVID-19 (2925)
CRISPR (89)
C-suite (920)
Cystic fibrosis (140)
Data (8356)
Decentralized trials (1)
Denatured (45)
Depression (168)
Dermatology (95)
Diabetes (661)
Diagnostics (5076)
Digital health (50)
Diversity (8)
Diversity, equity & inclusion (47)
Drug discovery (314)
Drug pricing (174)
Drug shortages (31)
Duchenne muscular dystrophy (285)
Earnings (63702)
Editorial (62)
Employer branding (24)
Employer resources (168)
Events (77361)
Executive appointments (831)
FDA (15785)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (22)
Frontotemporal dementia (30)
Funding (1519)
Gene editing (200)
Generative AI (59)
Gene therapy (682)
GLP-1 (1227)
Government (3969)
Grass and pollen (8)
Guidances (414)
Healthcare (13417)
Hematology (158)
HIV (94)
Huntington's disease (61)
IgA nephropathy (118)
Immunology and inflammation (304)
Immuno-oncology (107)
Indications (220)
Infectious disease (3245)
Inflammatory bowel disease (198)
Inflation Reduction Act (10)
Influenza (129)
Intellectual property (264)
Interviews (378)
IPO (13048)
IRA (44)
Job creations (2734)
Job search strategy (1340)
JPM (56)
Kidney cancer (24)
Labor market (123)
Layoffs (652)
Leadership (41)
Legal (4246)
Licensing (8)
Liver cancer (98)
Longevity (20)
Lung cancer (848)
Lymphoma (473)
Machine learning (45)
Management (64)
Manufacturing (920)
Marketing (12)
MASH (216)
Medical affairs (1)
Medical device (9228)
Medtech (9378)
Mergers & acquisitions (12154)
Metabolic disorders (1681)
mRNA (236)
Multiple sclerosis (191)
NASH (23)
Neurodegenerative disease (443)
Neuropsychiatric disorders (106)
Neuroscience (3244)
Neurotech (2)
NextGen: Class of 2026 (4530)
Non-profit (2845)
Now hiring (84)
Obesity (789)
Opinion (323)
Ovarian cancer (223)
Pain (238)
Pancreatic cancer (334)
Parkinson's disease (375)
Partnered (28)
Patents (515)
Patient recruitment (747)
Peanut (61)
People (32763)
Pharmaceutical (79)
Pharmacy benefit managers (22)
Phase 1 (18417)
Phase 2 (30171)
Phase 3 (21062)
Pipeline (9780)
Policy (242)
Postmarket research (1854)
Preclinical (6609)
Press Release (50)
Prostate cancer (326)
Psychedelics (60)
Radiopharmaceuticals (283)
Rare diseases (1114)
Real estate (3321)
Recruiting (79)
Regulatory (19010)
Reports (74)
Research institute (1986)
Resumes & cover letters (364)
Rett syndrome (46)
RNA editing (21)
RSV (81)
Schizophrenia (182)
Series A (259)
Series B (187)
Service/supplier (14)
Sickle cell disease (116)
Special edition (31)
Spinal muscular atrophy (169)
Sponsored (47)
Startups (2501)
State (2)
Stomach cancer (19)
Supply chain (88)
Tariffs (66)
The Weekly (103)
Vaccines (1133)
Venture capital (102)
Weight loss (538)
Women's health (110)
Worklife (22)
Date
Today (38)
Last 7 days (630)
Last 30 days (1824)
Last 365 days (25515)
2026 (15806)
2025 (25014)
2024 (28022)
2023 (30201)
2022 (40368)
2021 (43501)
2020 (40671)
2019 (33181)
2018 (24656)
2017 (22660)
2016 (20506)
2015 (24495)
2014 (17751)
2013 (13288)
2012 (14199)
2011 (14828)
2010 (13023)
Location
Africa (579)
Alabama (79)
Alaska (3)
Arizona (224)
Arkansas (10)
Asia (30815)
Australia (5221)
California (11676)
Canada (3234)
China (1454)
Colorado (482)
Connecticut (566)
Delaware (375)
Europe (71421)
Florida (1670)
Georgia (386)
Hawaii (4)
Idaho (37)
Illinois (927)
India (89)
Indiana (535)
Iowa (22)
Japan (543)
Kansas (102)
Kentucky (42)
Louisiana (52)
Maine (56)
Maryland (1331)
Massachusetts (8576)
Michigan (253)
Minnesota (563)
Mississippi (7)
Missouri (126)
Montana (17)
Nebraska (25)
Nevada (121)
New Hampshire (69)
New Jersey (3248)
New Mexico (21)
New York (3187)
North Carolina (1358)
North Dakota (5)
Northern California (5847)
Ohio (317)
Oklahoma (13)
Oregon (41)
Pennsylvania (2280)
Puerto Rico (32)
Rhode Island (35)
South America (793)
South Carolina (75)
Southern California (4699)
Tennessee (159)
Texas (1879)
United States (40984)
Utah (323)
Vermont (2)
Virginia (271)
Washington D.C. (66)
Washington State (922)
West Virginia (2)
Wisconsin (108)
482,531 Results for "2".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Job Trends
Bonus: Q2 2026 Job Market Update
In this bonus episode,
BioSpace
Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss encouraging signs for job seekers.
July 14, 2026
·
1 min read
·
Angela Gabriel
Press Releases
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
August 10, 2026
·
7 min read
Earnings
GSK shares rise as $2.5B cost-cutting plan unveiled
As GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.
July 28, 2026
·
4 min read
·
Gabrielle Masson
Job Trends
Report: Biopharma Job Market Report Q2 2026
Gain the latest insights into the biopharma hiring landscape with BioSpace’s Biopharma Job Market Report Q2 2026. Explore the trends shaping talent acquisition, from rising job postings and sustained R&D hiring to the market activity signaling stronger hiring demand ahead.
July 13, 2026
·
1 min read
·
BioSpace Insights
Metabolic disorders
Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate
Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome.
June 1, 2026
·
2 min read
·
Michael Gibney
Neuroscience
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
While MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb’s Cobenfy is likely to hold its market share.
July 27, 2026
·
2 min read
·
Michael Gibney
Opinion
The FDA’s 505(b)(2) pathway is an underestimated engine of value creation
The biopharma industry would do well to re-embrace the 505(b)(2) path, which allows sponsors to draw on previous findings around an existing drug even as they propose modifications to it.
July 21, 2026
·
6 min read
·
Gail McIntyre
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
The star of the takeover is Forte Biosciences’ investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
July 27, 2026
·
2 min read
·
Tristan Manalac
Business
GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail
Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.
July 17, 2026
·
1 min read
·
Tristan Manalac
Press Releases
LeMaitre Q2 2026 Financial Results
August 4, 2026
·
16 min read
1 of 48,254
Next
